Clik here to view.
モンロールとフューチャーケムが臨床供給に関する提携を発表
イスタンブール & ソウル （ビジネスワイヤ） — エジザージュバシュ・モンロール・ニュークリア・プロダクツ（モンロール）は、韓国のソウルに拠点を置く放射性医薬品企業フューチャーケムと、放射性同位元素である無担体ルテチウム-177（Lu-177 n.c.a.）の臨床供給につき大筋合意に達したことを発表します。Lu-177...
View ArticleClik here to view.
New Crown Bioscience Publication Details Application of In Vitro 3D Organoids...
SAN DIEGO Crown Bioscience, a JSR Life Sciences company and Contract Research Organization (CRO), has announced the publication of its review paper entitled: Translational and Clinical Relevance of...
View ArticleClik here to view.
SHI receives first order for next-generation proton therapy system from...
TOKYO Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (head office: Shinagawa City, Tokyo; President and CEO: Shinji Shimomura; hereinafter “SHI”) has received an order from Taichung Veterans General...
View ArticleClik here to view.
冠科生物新发表的论文详细介绍了体外3D类器官与匹配的PDX在临床相关肿瘤药物开发中的应用
圣迭戈 (美国商业资讯)–JSR Life Sciences旗下的合同研究组织(CRO)冠科生物(Crown Bioscience)日前发布了题为“PDX源性类器官模型在肿瘤学药物发现和开发中的转化和临床意义”的综述文章。...
View ArticleClik here to view.
クラウン・バイオサイエンスの新論文では、マッチング PDXによるIn Vitro 3Dオルガノイドの臨床的に意義のある抗がん剤開発への適用を詳述
サンディエゴ （ビジネスワイヤ） — JSRライフサイエンス傘下企業で医薬品開発業務受託機関（CRO）のクラウン・バイオサイエンスは、「抗がん剤の創薬・開発におけるPDX由来オルガノイドモデルの橋渡し的かつ臨床的な意義」（Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug...
View ArticleClik here to view.
MTTI Receives Chinese Patent for EVATHERA Technology
WEST CHESTER, Pa. Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its...
View ArticleClik here to view.
Clik here to view.
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients...
CORALVILLE, Iowa Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing...
View ArticleClik here to view.
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI
MINNEAPOLIS Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has...
View ArticleClik here to view.
TAE Life Sciences Announces First Cancer Patient Treatments Using...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that the first...
View ArticleClik here to view.
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of...
TOKYO Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head...
View ArticleClik here to view.
HPO, in Collaboration with Eastman, Announces Upcoming Launch of High Energy...
CHARLOTTE, N.C. Eastman and High Performance Optics, Inc. (HPO) announced today that a selective High Energy Visible Light (HEVL) filtering window film for the transportation industry will be...
View ArticleClik here to view.
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical...
KANAGAWA, Japan PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination...
View ArticleClik here to view.
Mitsubishi Electric Develops Tomographic Imaging Technology to Visualize...
TOKYO Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed what is believed to be the first industrial tomographic-imaging technology that uses a 300GHz terahertz wave...
View ArticleClik here to view.
MTTI Receives Chinese Patent for EVATHERA Technology
WEST CHESTER, Pa. Molecular Targeting Technologies, Inc. (MTTI) announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its...
View ArticleClik here to view.
Clik here to view.
Viewpoint Molecular Targeting Announces First Neuroendocrine Tumor Patients...
CORALVILLE, Iowa Viewpoint Molecular Targeting®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing...
View ArticleClik here to view.
Imricor Collaborates with GE HealthCare in Interventional Cardiac MRI
MINNEAPOLIS Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has...
View ArticleClik here to view.
TAE Life Sciences Announces First Cancer Patient Treatments Using...
FOOTHILL RANCH, Calif. TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that the first...
View ArticleClik here to view.
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of...
TOKYO Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head...
View Article